UNSPSC 51142558: Mofegiline hydrochloride

This classification denotes a monoamine oxidase inhibitor C11H13F2N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08331R10RY, chemically known as benzenebutanamine, 4-fluoro-.beta.-(fluoromethylene)-, hydrochloride, (e)-, but more generally known as mofegiline hydrochloride, which bears US NIH Compound Identifier 3047771. Most nations, for tariff and trade purposes, schedule mofegiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, MOFEGILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Mofegiline hydrochloride bears US NLM identifiers UMLS ID C2825395 and NCI Concept Code C80965. SMILES: C1CC(CCC1CC/C(=C\F)/CN)F.CL.

UNSPSC 51142558 Mofegiline hydrochloride is a Commodity code that does not align with recent state and local procurement activity in the source. The three recent opportunities posted under or near this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmaceutical prescriptions (Texas HHS Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations references mofegiline hydrochloride or compounds in that class; the code appears to have been assigned to opportunities focused on broader pharmaceutical distribution, community health supplies, and pharmacy benefit program infrastructure rather than the specific active pharmaceutical ingredient the code nominally describes.

The issuing bodies span county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing consortia (MMCAP, administered through Minnesota's Office of State Procurement). Activity is geographically dispersed across Florida, Texas, and Minnesota with multistate reach through MMCAP membership. Recent opportunities include an IFB for naloxone and drug deactivation systems (Seminole County, due July 26, 2026), an RFI on direct pharmacy contracting (Texas HHS, posted April 3, 2026), and an RFP for generic pharmaceuticals and OTC products (MMCAP, due March 26, 2026). The code shows little relevant recent activity tied to mofegiline hydrochloride specifically.